News | July 23, 2012

Medtronic Begins Global Trial Evaluating CoreValve for Intermediate-Risk Patients

July 23, 2012 — Medtronic Inc. announced the first patient enrollment in a global, multicenter, randomized clinical trial comparing the Medtronic CoreValve system with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk to undergo open heart surgery. The trial, called the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, will evaluate the potential for the minimally invasive CoreValve system to be considered for less-sick patients who typically are treated with open-heart surgical aortic valve replacement (SAVR) today.

The first patient procedures in the SURTAVI trial occurred at Rigshospitalet - Copenhagen University Hospital in Copenhagen, Denmark, and were performed by Lars Søndergaard, M.D., interventional cardiologist, and Daniel Steinbrüchel, M.D., DMSc, cardiaothoracic surgeon.

“Transcatheter aortic valve replacement is a transformational, potentially lifesaving technology that typically is used to treat inoperable patients or patients for whom surgery carries high risks,” said Patrick Serruys, M.D., Ph.D., professor of medicine and head of the department of interventional cardiology at Erasmus Medical Center in Rotterdam, The Netherlands, and chairman of the SURTAVI trial. “The SURTAVI trial will offer guidance on how to best treat intermediate risk patients and may substantiate the CoreValve System as an attractive alternative treatment for these patients.”

The trial will be the largest global, randomized, controlled trial on transcatheter aortic valve implantation (TAVI) and will nominally evaluate approximately 2,500 patients at up to 75 clinical sites with experienced heart teams that include interventional cardiologists and cardiac surgeons. The trial will evaluate whether the CoreValve system is non-inferior to surgical valve replacement, based on the composite primary endpoint of all-cause mortality and major stroke at 24 months. Medtronic is working with the U.S. Food and Drug Administration (FDA) to include U.S. patients in the trial.

Patients considered for the trial include those with severe, symptomatic aortic stenosis who are classified as intermediate surgical risk, as defined by a Society of Thoracic Surgeons’ (STS) mortality risk of ? 4 percent and ? 10 percent. Patients will be randomized on a 1:1 basis to either TAVI with CoreValve or to surgery. CoreValve implantation can be performed by transfemoral, subclavian or direct aortic access, depending on the needs of the patient. All patients will be followed through five years.

“We are pleased to begin this important trial that may demonstrate the benefits of the CoreValve system in a broader population of patients with severe aortic stenosis,” said A. Pieter Kappetein, M.D., Ph.D., principal investigator of the SURTAVI trial and professor of cardiothoracic surgery at Erasmus Medical Center. “This study represents a significant opportunity to bring a new therapy to physicians and a large percentage of patients, both of whom are looking for a less invasive option to treat aortic stenosis.”

The Medtronic CoreValve system received CE mark in 2007. It is available in three sizes (26 mm, 29 mm and 31 mm), and is the only TAVI system approved for implantation via the direct aortic approach and the subclavian approach. The CoreValve system is currently limited to investigational use in the United States.

For more information: www.medtronic.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init